Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

Core Insights - Nuvectis Pharma, Inc. has appointed Dr. Juan Sanchez to its Board of Directors, bringing extensive experience in biotech and capital markets [1][3] - Dr. Sanchez previously served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, which was acquired by Johnson & Johnson for $14.6 billion in April 2025 [2][3] - The company is entering a new growth phase with the initiation of the Phase 1b program for its lead drug candidate, NXP900, aimed at treating advanced and treatment-resistant cancers [3][4] Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious unmet medical needs in oncology [4] - The lead program, NXP900, is an oral small molecule inhibitor targeting SRC Family of Kinases (SFK), having completed a Phase 1a dose escalation study and currently being evaluated in a Phase 1b program [4] - The company is also exploring next steps for NXP800, which has shown anti-cancer activity in specific ovarian cancer cases [4] Dr. Juan Sanchez's Background - Dr. Sanchez has over 30 years of experience in healthcare, combining roles in patient care, research analysis, and executive leadership in biopharmaceuticals [3] - His tenure at Intra-Cellular Therapies included the successful development and commercialization of CAPLYTA (lumateperone) [3] - Dr. Sanchez holds advanced degrees in International Affairs, Business Administration, and Medicine, and has practiced medicine for five years in Colombia [3]